证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 编号：2022-035 | --- | --- | --- | |-----------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2022-034 证券代码：301166 证券简称：优宁维 上海优宁维生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|----------|-------------------------------------------------------------|-----------------------------------------| | 投资者关系活动 \n类别 | \n 其他 | 特定对象调研 媒体采访 \n新闻发布会 \n现场参观 \n( 电话会议) | 分析师会议 业绩说明会 \n 路演活动 \n | | | 冯 瑞 | 山西证券 | | | | 龚宇琼 | 歌斐资产 | | | | 陆伏崴 | 西部证券 | | | | 曹聪聪 | 光大证券研究所 | | | | 凌静怡 | 申万宏源 | | | | 陈嘉烨 | 西部证券 | | | | 林小伟 | 汇添富基金管理股份有限公司 | | | | | | | | | 冯 瑞 | 山西证券 | | | | 魏 赟 | 山证研究所 | | | ...

上海优宁维生物科技股份有限公司 2022 年第三季度报告 证券代码：301166 证券简称：优宁维 公告编号：2022-076 上海优宁维生物科技股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 单位：元 | | 本报告期 | 本报告期比上年 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 同期增减 | | 比上年同期增减 | | 营业收入（元） | 359,167,560.95 | 26.21% | 861,791,858.97 | 8.68% | | 归属于上市公司股东的净利润（元） | 38,138,403.87 | ...

Capital Structure and Financial Position - The company reported a registered capital increase from RMB 65 million to RMB 86.67 million, with total shares rising from 65 million to 86.67 million[22]. - The company’s registered capital is RMB 86.67 million[200]. - The total number of shares after the recent changes is 86,666,668, with 75.01% being restricted shares[151]. - The company has a unified social credit code of 91310000768354199F[200]. - The total equity attributable to shareholders at the end of the period is 86.66 million, reflecting a decrease from 66.6 million in the previous year[190]. - The total assets of the company are reported at 1.72 billion, indicating a strong asset base for future growth[190]. - The total assets at the end of the current period are reported at 2,012 million, reflecting a stable financial position[194]. - The total equity at the end of the current period stands at 2,000 million, with a capital reserve of 1,720 million and a surplus reserve of 168.4 million[195]. - The company’s capital reserve increased by 141 million yuan, contributing to overall equity growth[192]. - The total comprehensive income for the current period is 6,586 million, reflecting a decrease of 5,567 million compared to the previous period[194]. Revenue and Profitability - The company's operating revenue for the reporting period was ¥502,624,298.02, a decrease of 1.14% compared to ¥508,397,930.95 in the same period last year[23]. - The net profit attributable to shareholders decreased by 20.09% to ¥40,862,787.50 from ¥51,134,181.23 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was ¥35,171,997.72, down 25.27% from ¥47,066,198.95 in the previous year[23]. - The company reported a significant increase in revenue for the first half of 2022, achieving a total revenue of 500 million RMB, representing a 25% year-over-year growth[104]. - The company reported a total revenue of 262.09 million, which is a significant increase from 560.25 million in the previous period[190]. - The company reported a profit distribution of RMB 20.15 million to shareholders[198]. - The company reported a net profit margin of approximately 9.93% for the first half of 2022, down from 11.93% in the same period of 2021[177]. - The company’s retained earnings at the end of the period were 1,410.54 million yuan, indicating a strong financial position[192]. Research and Development - The company has a focus on research and development in biotechnology, particularly in immunology and molecular biology[14]. - The company successfully developed 24 recombinant antigen products and 5 pathological IHC antibodies during the reporting period, contributing to its product portfolio[40]. - The company is investing heavily in R&D, with a budget increase of 30% for new technology development[103]. - The company is investing in R&D, with a budget increase of 20% for new technology development in the upcoming fiscal year[105]. - The company has allocated 10 million for R&D in the upcoming year to support new technology advancements[106]. - Research and development expenses increased to CNY 10.88 million, up 85.3% from CNY 5.87 million in the previous year[181]. Market Expansion and Product Development - The company has accumulated over 670,000 business orders and served more than 14,000 clients, covering over 100,000 researchers[34]. - The company launched new products, including COVID-19 variant Omicron antigens and monkeypox virus protein antigens, for in vitro diagnostic reagent core materials[40]. - Market expansion plans include entering three new international markets by the end of 2022[103]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[103]. - The company plans to continue its market expansion efforts, focusing on new product development and technological advancements[188]. - The company is exploring potential mergers and acquisitions to enhance its market position and expand its product offerings[188]. Operational Efficiency and Challenges - The company’s management discusses potential risks and countermeasures in the report[4]. - The ongoing COVID-19 pandemic has caused operational disruptions, particularly in Shanghai, affecting business performance[99]. - The company is monitoring the pandemic situation closely and implementing measures to reduce its impact on business operations[99]. - The company aims to enhance its gross margin by expanding its product offerings and increasing the proportion of high-margin self-branded products[100]. - The company has implemented strategic measures to enhance operational efficiency and improve profitability margins[193]. - The company aims to reduce operational costs by 15% through efficiency improvements in the supply chain[105]. Financial Management and Investments - The company plans to use up to RMB 120,000.00 million of idle raised funds and up to RMB 80,000.00 million of self-owned funds for cash management, valid for 12 months from the date of approval[80]. - The company has committed to investing 25 million CNY in a private equity fund managed by a related party, with the first phase of investment completed at 7.5 million CNY[135]. - The company has allocated 20.1 million yuan for general risk reserves, demonstrating a proactive approach to financial management[193]. - The company reported a significant increase in cash outflow for investment activities, reflecting aggressive investment strategies[184]. - The company has not engaged in any derivative investments during the reporting period[91]. Shareholder Information and Corporate Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company held its first temporary shareholders' meeting on March 9, 2022, with an investor participation rate of 48.97%[111]. - The second temporary shareholders' meeting took place on June 27, 2022, with a participation rate of 50.35%[111]. - The total number of common shareholders at the end of the reporting period is 16,547[155]. - The largest shareholder, Leng Zhaowu, holds 33.09% of the shares, totaling 28,674,000 shares[155]. - The company has not experienced any major changes in the feasibility of its projects during the reporting period[87].

上海优宁维生物科技股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司 2022 年第一季度报告全文 证券代码：301166 证券简称：优宁维 公告编号：2022-039 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | ロ た ▼ 日 | | --- | 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 241,570,107.45 | 235,850,030.87 | 2.43% | | 归属于上市公司股东的净利润（元） | 21,729,548.27 | 21,344,192.74 | 1.81% | | 归属于上市公司股东的扣除非经常性损益的 净利润（元） | 21,270,554 ...

Financial Performance - The company reported a profit distribution plan of 5.00 RMB per 10 shares (including tax) for all shareholders, based on a total of 86,666,668 shares[5]. - The company's operating revenue for 2021 was ¥1,109,667,928.51, representing a 30.69% increase compared to ¥849,080,674.51 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥108,728,231.17, a 42.15% increase from ¥76,487,842.98 in 2020[18]. - The net profit after deducting non-recurring gains and losses was ¥101,963,311.26, up 42.30% from ¥71,652,941.98 in 2020[18]. - The total assets at the end of 2021 reached ¥2,313,053,372.17, a significant increase of 291.48% from ¥590,854,410.45 at the end of 2020[18]. - The net assets attributable to shareholders increased by 415.89% to ¥2,088,255,081.32 at the end of 2021 from ¥404,790,481.75 at the end of 2020[18]. - The basic earnings per share for 2021 was ¥1.66, a 40.68% increase from ¥1.18 in 2020[18]. - The company reported a net cash flow from operating activities of ¥59,022,956.47, a decrease of 36.00% compared to ¥92,227,783.01 in 2020[18]. - The company achieved sales revenue from self-produced products of 1,030.32 million RMB in 2021, up from 565.64 million RMB in 2020, indicating a growth rate of approximately 82.2%[48]. - The company reported a continuous increase in demand for research products and services due to rising investments in scientific research and the heightened importance of life sciences following the COVID-19 pandemic[51]. - In 2021, the company achieved a revenue of CNY 1,109.67 million, representing a year-on-year growth of 30.69%[59]. - The net profit attributable to shareholders reached CNY 108.73 million, an increase of 42.15% compared to the previous year[59]. - The company’s gross margin for its main business is reported at 23.19%, which may fluctuate due to changes in revenue structure and competitive pressures[96]. Market and Industry Insights - The company operates in the scientific services industry, focusing on life science reagents, instruments, and consumables, with a growing market presence[27]. - The domestic market for life science reagents is heavily reliant on imports, with 83% of transactions in key projects involving imported reagents as of 2020[28]. - China's R&D expenditure increased from CNY 1,029.8 billion in 2012 to CNY 2,786.4 billion in 2021, with a CAGR of 11.69%[29]. - R&D expenditure as a percentage of GDP reached 2.44% in 2021, with a target of 2.5% by 2020 and 2.8% by 2030[31]. - The global life sciences reagents market is projected to reach USD 13.277 billion by 2023, with a CAGR of 6.5% from 2018 to 2023[32]. - The disposable life sciences consumables market in China was valued at CNY 23.126 billion in 2018, with an expected annual growth rate of 20%[35]. - Domestic life sciences reagent market share for local brands is approximately 10%, indicating significant competition from international firms[36]. - The life sciences reagent industry in China is entering a critical development phase, with expectations of increased market consolidation and higher concentration levels[37]. - E-commerce is expected to grow in the life sciences reagent industry, driven by diverse customer needs and frequent purchasing patterns[37]. Research and Development - The company’s R&D efforts focus on antibody core application technologies, with significant investments in developing products such as recombinant proteins and paired antibodies[49]. - The company’s R&D expenses increased by 91.99% to ¥16,768,107.84, reflecting a significant investment in research and development[75]. - The number of R&D personnel increased to 64 in 2021, a rise of 52.38% from 42 in 2020, with the proportion of R&D staff in total employees increasing from 9.44% to 12.98%[77]. - The company completed the development of multiple rabbit polyclonal antibodies, enhancing its product pipeline and market competitiveness[76]. - The company developed a multi-color staining technology that allows simultaneous marking of 6-9 different indicators on a single slice, improving its research and clinical diagnostic capabilities[76]. - The company plans to develop 10-20 immune checkpoint protein products and multiple antibody products to strengthen its market position in the recombinant protein sector[77]. Sales and Marketing Strategy - The company has established a nationwide sales network with 32 offices and 5 subsidiaries, primarily relying on offline sales while utilizing an online platform for additional customer acquisition[45]. - The company has a self-owned e-commerce platform with over 107,600 registered users, enhancing its market reach[40]. - The company’s sales model combines direct sales and distribution, leveraging a team of professionals in biology and computer technology to provide a one-stop service platform[52]. - The company aims to enhance its brand image as a "one-stop service provider" in life sciences through continuous product line expansion and technical support services[59]. - The company plans to increase its marketing budget by 15% in 2022 to boost brand awareness and customer acquisition[160]. Corporate Governance and Compliance - The company emphasizes information disclosure, ensuring that all shareholders have equal access to information through designated media[103]. - The company maintains complete independence in assets, personnel, finance, and operations from its controlling shareholder[105][106]. - The company has established a comprehensive performance evaluation system for senior management, linking their performance directly to compensation[103]. - The company held 4 shareholder meetings in 2021, all of which were conducted before the IPO, with all resolutions passed legally and effectively[101]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of 1/3 independent directors[102]. - The company has a structured remuneration system based on basic salary, performance pay, and allowances[123]. - The company has implemented a performance management mechanism linking year-end bonuses to individual performance, promoting innovation and high technical standards[151]. Future Outlook and Strategic Initiatives - The company provided guidance for 2022, projecting a revenue growth of 30% to 1.56 billion RMB, driven by new product launches and market expansion[120]. - The company plans to pursue strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for potential targets[169]. - The company is expanding its market presence in Southeast Asia, targeting a 15% market share by the end of 2023[120]. - The company aims to enhance the efficiency of raised funds and accelerate the construction of investment projects to achieve expected benefits[164]. - The company is committed to innovation in biotechnology, aiming to enhance its product offerings and market competitiveness[111]. Social Responsibility and Community Engagement - The company donated RMB 200,000 to support flood-affected areas in Henan in July 2021 and provided free research reagents to local researchers[153]. - The company actively participates in social welfare initiatives, including providing living supplies to Shanghai Jiao Tong University during the pandemic in March 2022[153]. Stock and Shareholder Information - The company completed its initial public offering (IPO) of 21,666,668 shares of RMB ordinary shares (A-shares), increasing the total share capital from 65,000,000 to 86,666,668 shares[199]. - The total number of restricted shares increased to 66,152,671, representing 76.33% of the total shares post-IPO[199]. - The company guarantees to strictly fulfill the commitments disclosed in the prospectus for its initial public offering[165]. - The company will compensate investors for losses incurred due to non-fulfillment of commitments, as determined by regulatory authorities[165].